Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SPTX
SPTX logo

SPTX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
17.690
Open
17.190
VWAP
17.24
Vol
214.58K
Mkt Cap
886.69M
Low
16.530
Amount
3.70M
EV/EBITDA(TTM)
--
Total Shares
50.67M
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Events Timeline

(ET)
2026-05-04
11:50:00
Pershing Square USA and Inc. Begin Trading on April 29
select
2026-05-01 (ET)
2026-05-01
12:40:00
Seaport Therapeutics Prices 14.2M Shares at $18.00
select
2026-05-01
07:30:00
Goldman Sachs and Others Increase Stock Offering Size to 14.2M Shares
select

News

CNBC
6.0
13:03 PMCNBC
Latest Wall Street Rating Updates
  • Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
  • Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
  • Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
  • Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
Newsfilter
8.5
05-08Newsfilter
Odyssey Therapeutics Raises $279 Million in Upsized IPO
  • Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
  • Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
  • Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
  • Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
renaissancecapital
8.5
05-01renaissancecapital
Strong IPO Performance from Biotech Firms
  • Biotech Financing Success: Hemab Therapeutics raised $302 million, achieving an $849 million market cap, focusing on antibody therapies for blood coagulation disorders, with its lead candidate poised for Phase 3 trials, which is expected to significantly enhance the company's competitive edge in the biopharmaceutical market.
  • Pulmonary Fibrosis Treatment Progress: Avalyn Pharma also completed its IPO with $300 million raised and an $813 million market cap, concentrating on inhaled antifibrotic therapies for rare respiratory diseases, with key clinical data expected in mid-2027, potentially driving long-term growth for the company.
  • Neuropsychiatric Drug Development: Seaport Therapeutics successfully raised $255 million, reaching a $1.1 billion market cap, focusing on treatments for neuropsychiatric disorders, with its lead program GlyphAllo in Phase 2b trials, which could further solidify its market position if successful.
  • Mining Company IPO Underperformance: Silver Bow Mining raised $60 million with a market cap of $368 million, focusing on various mineral resources but has yet to generate revenue, with a 7% drop in stock price on its first day, indicating market caution regarding its prospects.
seekingalpha
8.5
05-01seekingalpha
Hemab and Seaport Shares Surge on Strong IPO Debuts
  • Hemab's Debut Performance: Hemab Therapeutics priced its IPO at $18 per share, opening at $27, reflecting a ~50% increase, and reaching $29.68 by 1:30 PM ET, indicating strong market confidence in its bleeding disorder treatments.
  • Seaport's Stock Surge: Seaport Therapeutics also priced its IPO at $18, opening at $21, a ~17% rise, and climbing to $22.51 by 1:30 PM ET, showcasing investor optimism regarding its neuropsychiatric drug development.
  • Significant Fundraising: The two companies collectively raised over $550 million through upsized IPOs, with Hemab expecting $301.5 million and Seaport $254.9 million, providing robust funding for future R&D and market expansion.
  • Positive Market Reaction: The successful listings of both companies not only highlight the vitality of the biotech sector but also reflect investor confidence in new drug development, particularly driven by positive clinical trial results, potentially attracting more attention to this field.
seekingalpha
8.5
05-01seekingalpha
Hemab and Seaport Price IPOs to Raise Over $550M
  • Hemab IPO Details: Hemab Therapeutics priced its IPO at $18.00 per share for 16.75 million shares, raising approximately $301.5 million, indicating strong market demand for its bleeding disorder treatments and solidifying its position in the biotech sector.
  • Seaport IPO Pricing: Seaport Therapeutics priced nearly 14.2 million shares at $18.00 each, expecting to raise about $254.9 million, reflecting investor confidence in its neuropsychiatric drug development and providing crucial funding support in a competitive biopharmaceutical market.
  • Underwriter Options: Both companies have granted underwriters a 30-day option, with Hemab allowing for an additional 2.5 million shares and Seaport 2.1 million shares, a strategy that not only provides additional funding flexibility but could also enhance fundraising if market demand remains strong.
  • Market Response and Timeline: Both firms aim to close their offerings on May 4, and the positive market response to these IPOs may drive overall investment enthusiasm in the biotech sector, attracting more investor attention to emerging biopharmaceutical companies.
renaissancecapital
8.5
05-01renaissancecapital
April IPO Market Rebounds with $7.3 Billion Raised
  • Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
  • Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
  • Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
  • Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
Wall Street analysts forecast SPTX stock price to rise
0 Analyst Rating
Wall Street analysts forecast SPTX stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for Seaport Therapeutics, Inc. (SPTX.O) is 0.00, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Seaport Therapeutics, Inc.'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
Current PE
0.00
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
Current PS
0.00
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding SPTX

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Seaport Therapeutics, Inc. (SPTX) stock price today?

The current price of SPTX is 17.5 USD — it has increased 1.8

What is Seaport Therapeutics, Inc. (SPTX)'s business?

What is the price predicton of SPTX Stock?

Wall Street analysts forecast SPTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Seaport Therapeutics, Inc. (SPTX)'s revenue for the last quarter?

Seaport Therapeutics, Inc. revenue for the last quarter amounts to NaN USD, decreased

What is Seaport Therapeutics, Inc. (SPTX)'s earnings per share (EPS) for the last quarter?

Seaport Therapeutics, Inc.. EPS for the last quarter amounts to USD, decreased

How many employees does Seaport Therapeutics, Inc. (SPTX). have?

Seaport Therapeutics, Inc. (SPTX) has 0 emplpoyees as of May 26 2026.

What is Seaport Therapeutics, Inc. (SPTX) market cap?

Today SPTX has the market capitalization of 886.69M USD.